ClinicalTrials.gg
CompletedNCT00529126Updated Mar 4, 2021Results posted

Phase 2 Dose-Ranging Study of SKY0402 for Prolonged Postoperative Analgesia in Subject Undergoing Hemorrhoidectomy

A Phase 2 interventional study of SKY0402 and Bupivacaine HCl in Postoperative Pain, sponsored by Pacira Pharmaceuticals, Inc. Completed at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-04.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Enrollment
97th of 364
100 · median 70
Started
2007
with 6 others
Phase 2
43 of 364
4 open now
Registered
9th of 364
by date
Lead sponsor
22 of 364
Pacira Pharmaceuticals, Inc

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 97th largest by enrollment, is one of 7 that started in 2007, is one of 43 in phase 2, and was the 9th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

Phase 2 study to evaluate three dose levels of SKY0402 compared with 75 mg of bupivacaine HCl.

Read the detailed description

Effective postoperative pain control is a critical element in patient recovery, as the majority of patients may experience significant pain, particularly in the first few days following surgery. Appropriate postoperative pain management contributes to improved healing, faster patient mobilization, shortened hospital stays, and reduced healthcare costs.

03

Conditions studied

  • Postoperative Pain

Keywords

  • hemorrhoidectomy
  • pain
  • Postoperative
  • analgesia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, 18 years of age and older at the Screening Visit.
  2. Applies to female subjects only: , surgically sterile, or willing to use acceptable means of for at least 30 days after surgery including any of the following: hormonal contraceptives (e.g., oral, injectable, implantable starting at least 30 days before study drug administration), effective double-barrier methods (e.g., condoms with spermicide), intrauterine device, lifestyle with a personal choice of abstinence, nonheterosexual lifestyle, or a strictly monogamous relationship with a partner who has had a vasectomy.
  3. Scheduled to undergo 2- or 3-column excisional hemorrhoidectomy under general anesthesia using Milligan Morgan or Ferguson-type techniques, including modified approaches with specialized instruments, such as LigaSure™ or harmonic scalpel, with a cumulative incision length of a minimum 3 cm.
  4. American Society of Anesthesiology (ASA) Physical Class 1-3.
  5. Able and willing to comply with all study visits and procedures.
  6. Able to speak, read, and understand the language of the Form (ICF), study questionnaires, and other instruments used for collecting subject-reported outcomes, in order to enable accurate and appropriate responses to pain scales and other required study assessments.
  7. Willing and capable of providing written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy, nursing, or planning to become pregnant during the study or within one month after study drug administration.
  2. Use of any of the following medications within the times specified before surgery:

    • Long-acting opioid medication within 3 days.
    • Any opioid medication within 24 hours.
  3. Concurrent painful physical condition that may require analgesic treatment in the postoperative period for pain that is not surgically related and may confound the postoperative assessments (e.g., rheumatoid arthritis, chronic neuropathic pain).
  4. Single-column hemorrhoidectomy or hemorrhoidectomy without an internal component.
  5. Body weight less than 50 kilograms (110 pounds).
  6. History of or idiosyncratic reactions to amide-type local anesthetics or to opioid medication.
  7. to epinephrine, such as concurrent administration of monoamine oxidase (MAO) inhibitors or antidepressants of amitriptyline or imipramine types, conditions where the production or exacerbation of tachycardia could prove fatal (e.g., poorly controlled thyrotoxicosis or severe heart disease), or any other pathological conditions that might be aggravated by the effects of epinephrine.
  8. Contraindications to any of the pain-control agents planned for postoperative use (e.g., acetaminophen [paracetamol], oxycodone, morphine, ketorolac).
  9. Administration of an drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
  10. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
  11. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the Investigator, may interfere with study assessments or compliance.
  12. Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicate an increased vulnerability to study drugs and procedures, and expose the subject to an unreasonable risk as a result of participating in this clinical trial, such as: debilitating diseases, acute illnesses, hypotension, partial or complete conduction block, impaired cardiac function, untreated hypertension, advanced arteriosclerotic heart disease, cerebral vascular insufficiency, pre-existing abnormal neurological or neuromuscular disease (e.g., epilepsy, myasthenia gravis), advanced liver disease, severe renal impairment, advanced diabetes, comorbid conditions associated with an status, such as blood dyscrasias, /AIDS, or recent chemotherapy.

    In addition, the subject will be ineligible to receive study drug if he or she meets the following criteria during surgery:

  13. Any event or condition uncovered during the surgery (e.g., excessive bleeding, acute sepsis) that might render the subject medically unstable or complicate the subject's postoperative course.
  14. A cumulative incision length less than 3 cm.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    SKY0402 high dose

    SKY0402, single administration

    Drug: SKY0402

  • Experimental
    SKY0402 middle dose

    SKY0402, single administration

    Drug: SKY0402

  • Experimental
    SKY0402 low dose

    SKY0402, single administration

    Drug: SKY0402

  • Active comparator
    Bupivacaine HCl

    Bupivacaine HCl

    Drug: Bupivacaine HCl

Interventions

  • SKY0402

    Also known as: EXPAREL

  • Bupivacaine HCl

    Also known as: Marcaine 0.25% with epinephrine 1:200,000

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) at Rest (NRS-R) Pain Intensity Scores From 0 Through 72 Hours

    To assess pain intensity at rest (NRS-R), the subject was to assume a resting position that did not exacerbate his or her postoperative pain. The subject was to rest in this position for at least 5 minutes before responding to the following question: "On a scale of 0 to 10, where 0=no pain and 10=worst possible pain, how much pain are you having right now?"

    Time frame: 0 to 72 hours

Secondary outcomes

  1. Participants With Adverse Events Through 72 Hours or Serious Adverse Events Through 30 Days

    Time frame: Up to 30 days

07

Results

Posted Aug 6, 2013

Participant flow

Participant flow — Overall Study
MilestoneSKY0402 High Dose (300mg)SKY0402 Middle Dose (225mg)SKY0402 Low Dose (75mg)Bupivacaine HCl 75mg
Started25252426
Completed25252426
Not completed0000

Outcome measures

PrimaryArea Under the Curve (AUC) of the Numeric Rating Scale (NRS) at Rest (NRS-R) Pain Intensity Scores From 0 Through 72 Hours

To assess pain intensity at rest (NRS-R), the subject was to assume a resting position that did not exacerbate his or her postoperative pain. The subject was to rest in this position for at least 5 minutes before responding to the following question: "On a scale of 0 to 10, where 0=no pain and 10=worst possible pain, how much pain are you having right now?"

Time frame:
0 to 72 hours
Reported as:
Mean · units on a scale*hrs
Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) at Rest (NRS-R) Pain Intensity Scores From 0 Through 72 Hours
units on a scale*hrsSKY0402 300mgSKY0402 225mgSKY0402 75mgBupivacaine HCl
Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) at Rest (NRS-R) Pain Intensity Scores From 0 Through 72 Hours175 ± 173172 ± 146225 ± 185331 ± 175
SecondaryParticipants With Adverse Events Through 72 Hours or Serious Adverse Events Through 30 Days
Time frame:
Up to 30 days

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SKY0402 High Dose—0/25 (0%)0/25 (0%)
SKY0402 Middle Dose—0/25 (0%)7/25 (28%)
SKY0402 Low Dose—1/24 (4.2%)7/24 (29.2%)
Bupivacaine HCl—0/26 (0%)10/26 (38.5%)
Most frequent serious events
Most frequent serious events
EventSKY0402 High DoseSKY0402 Middle DoseSKY0402 Low DoseBupivacaine HCl
Rectal hemorrhageVascular disorders0/250/251/240/26
Most frequent other events
Most frequent other events
EventSKY0402 High DoseSKY0402 Middle DoseSKY0402 Low DoseBupivacaine HCl
ConstipationGastrointestinal disorders0/255/253/244/26
NauseaGastrointestinal disorders0/254/253/243/26
VomitingGastrointestinal disorders0/253/251/243/26

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)SKY0402 High DoseSKY0402 Middle DoseSKY0402 Low DoseBupivacaine HClTotal
<=18 years00000
Between 18 and 65 years2324232595
>=65 years21115
Age, Continuous
Age, Continuous(years)SKY0402 High DoseSKY0402 Middle DoseSKY0402 Low DoseBupivacaine HClTotal
Mean45.5 ± 11.341.7 ± 11.242.2 ± 11.544.2 ± 10.643.4 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)SKY0402 High DoseSKY0402 Middle DoseSKY0402 Low DoseBupivacaine HClTotal
Female3971130
Male2216171570
Region of Enrollment
Region of Enrollment(participants)SKY0402 High DoseSKY0402 Middle DoseSKY0402 Low DoseBupivacaine HClTotal
United States5991437
Georgia2016151263
08

Study locations

7 sites
  • Accurate Clinical Trials, Inc.
    San Clemente, California 92673, United States
  • University of Miami/Jackson Memorial
    Miami, Florida 33136, United States
  • The Women's Hospital of Texas
    Houston, Texas 77054, United States
  • Multicare Health Systems Laboratories
    Tacoma, Washington 98405, United States
  • JSC Imereti Regional Clinical Hospital of the Name A. Dzotsenidze
    Kutaisi, 4600, Georgia
  • JSC K. Eristavi National Center of Experimental and Clinical Surgery
    Tbilisi, 0159, Georgia
  • Socieety with limited responsibility Proctology Center
    Tbilisi, 0160, Georgia
09

References and documents

Publications

  • Dasta J, Ramamoorthy S, Patou G, Sinatra R. Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting. Curr Med Res Opin. 2012 Oct;28(10):1609-15. doi: 10.1185/03007995.2012.721760. Epub 2012 Sep 3. PubMed 22900785 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Dec 2007 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 5 years 8 months after primary completion. A results delay was requested in Aug 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2007
First posted
Sep 14, 2007
Start
Sep 2007
Primary completionActual
Dec 2007
CompletionActual
Jul 2008
Results delay requested
Aug 25, 2010
Results first posted
Aug 6, 2013
Last update
Mar 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00529126
Responsible party
Sponsor
First posted
Sep 14, 2007
Start date
Sep 2007
Primary completion
Dec 2007
Completion
Jul 2008
Results posted
Aug 6, 2013
Last update
Mar 4, 2021

Study contacts

Erol Onel, MD
study director · Pacira Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion